MA50175A - Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés - Google Patents

Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés

Info

Publication number
MA50175A
MA50175A MA050175A MA50175A MA50175A MA 50175 A MA50175 A MA 50175A MA 050175 A MA050175 A MA 050175A MA 50175 A MA50175 A MA 50175A MA 50175 A MA50175 A MA 50175A
Authority
MA
Morocco
Prior art keywords
valbenazine
kits
dosage
formulation
methods
Prior art date
Application number
MA050175A
Other languages
English (en)
Inventor
Gregory A Mcclelland
Richard Alexander Moore Jr
Christopher F O'brien
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63794661&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50175(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of MA50175A publication Critical patent/MA50175A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
MA050175A 2017-09-21 2018-09-18 Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés MA50175A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762561629P 2017-09-21 2017-09-21
US201762564951P 2017-09-28 2017-09-28

Publications (1)

Publication Number Publication Date
MA50175A true MA50175A (fr) 2021-04-21

Family

ID=63794661

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050175A MA50175A (fr) 2017-09-21 2018-09-18 Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés

Country Status (12)

Country Link
US (3) US20200276184A1 (fr)
EP (1) EP3684333A2 (fr)
JP (1) JP7250006B2 (fr)
CN (1) CN111372567B (fr)
AU (1) AU2018335259A1 (fr)
BR (1) BR112020005373A2 (fr)
CA (1) CA3076000A1 (fr)
IL (3) IL309802A (fr)
MA (1) MA50175A (fr)
MX (1) MX2020002841A (fr)
TW (1) TW201919622A (fr)
WO (1) WO2019060322A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115322188A (zh) 2015-10-30 2022-11-11 纽罗克里生物科学有限公司 Valbenazine盐及其多晶形物
CN108925135A (zh) 2015-12-23 2018-11-30 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
JP7090151B2 (ja) 2017-01-27 2022-06-23 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
MX2020002841A (es) 2017-09-21 2020-07-22 Neurocrine Biosciences Inc Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma.
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors
EP3733666B1 (fr) 2017-12-26 2022-09-21 Crystal Pharmaceutical (Suzhou) Co., Ltd. Forme cristalline de di-p-toluènesulfonate de valbénazine, procédé de préparation associé et utilisation correspondante
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
WO2020037022A1 (fr) 2018-08-15 2020-02-20 Neurocrine Biosciences, Inc. Procédés d'administration de certains inhibiteurs de vmat2
US10940141B1 (en) * 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
TW202124377A (zh) 2019-09-13 2021-07-01 美商紐羅克里生物科學有限公司 戊苯那嗪（ｖａｌｂｅｎａｚｉｎｅ）之合成方法
EP4330255A1 (fr) 2021-04-26 2024-03-06 Neurocrine Biosciences, Inc. Procédés de synthèse de valbénazine

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5283918A (en) 1976-01-01 1977-07-13 Wellcome Found Pharmaceutical composition
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5777697A (en) 1980-11-04 1982-05-15 Nippon Zoki Pharmaceut Co Ltd Physiologically active substance nsq
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
JPS57209225A (en) 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
JPS6028987A (ja) 1983-07-28 1985-02-14 Chugai Pharmaceut Co Ltd 新規ジゴキシン誘導体
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
WO1997001331A2 (fr) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Production de preparations a liberation prolongee
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
KR100353304B1 (ko) 1996-10-01 2002-09-30 에스알아이 인터내셔널 맛이 차폐된 마이크로캡슐 조성물 및 이것의 제조 방법
CA2217134A1 (fr) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Formulation a liberation-retard
DE69730093T2 (de) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter Freisetzung
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
ZA9711385B (en) 1996-12-20 1999-06-18 Takeda Chemical Industries Ltd Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
WO2000024399A1 (fr) 1998-10-23 2000-05-04 Sepracor Inc. Compositions et procedes utilisant r(-) fluoxetine et autres composants actifs
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
AP2001002264A0 (en) 2000-08-30 2001-09-30 Pfizer Prod Inc Sustained release formulations for growth hormone secretagogues.
AU2003240818B2 (en) 2002-05-28 2006-05-04 Bette Pollard Cardiac glycosides to treat cystic fibrosis and other IL-8 dependent disorders
AU2003272608A1 (en) 2002-09-19 2004-04-08 University Of Utah Research Foundation Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease
GB0307259D0 (en) 2003-03-28 2003-05-07 Glaxo Group Ltd Process
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
KR20130099228A (ko) 2004-06-04 2013-09-05 제넨테크, 인크. 다발성 경화증의 치료 방법
CN1980943A (zh) 2004-07-05 2007-06-13 索尔维亚斯股份公司 具有2,2'－键接的非手性或手性基团的1,1'－二膦二茂铁
DE602005011468D1 (de) 2004-10-28 2009-01-15 Wyeth Corp Gemeinsame gabe von tigecyclin und digoxin
WO2006053067A2 (fr) 2004-11-09 2006-05-18 Prestwick Pharmaceuticals, Inc. Traitement de l'hypercinesie associant l'amantadine a un compose tetrabenazinique
ES2318771T3 (es) 2005-08-06 2009-05-01 Cambridge Laboratories (Ireland) Limited 3,11b-cis-dihidrotetrabenazinas para el tratamiento de la esquizofrenia y otras psicosis.
US20100076087A1 (en) 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
GB0721669D0 (en) 2007-11-02 2007-12-12 Cambridge Lab Ireland Ltd Pharmaceutical compounds
EP2233474B1 (fr) 2008-01-18 2015-08-05 Eisai R&D Management Co., Ltd. Dérivé d'aminodihydrothiazine condensée
DE102008012015A1 (de) * 2008-03-01 2009-09-10 Südzucker AG Mannheim/Ochsenfurt Verbesserte Isomalt-haltige Komprimate und Verfahren zu ihrer Herstellung
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463452A (en) 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
ES2652289T3 (es) 2008-09-18 2018-02-01 Auspex Pharmaceuticals, Inc. Derivados deuterados de benzoquinolina como inhibidores del transportador de monoamina vesicular 2
US20100096319A1 (en) 2008-10-17 2010-04-22 General Electric Company Separator assembly
EP2393484A1 (fr) * 2009-02-06 2011-12-14 Egalet Ltd. Composition à libération immédiate résistant à une maltraitance par prise d'alcool
ES2792126T3 (es) 2009-04-06 2020-11-10 Vanda Pharmaceuticals Inc Método de tratamiento basado en polimorfismos del gen KCNQ1
EP2464340A2 (fr) 2009-08-12 2012-06-20 Valeant International (Barbados) SRL Compositions pharmaceutiques
CA2801061A1 (fr) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Inhibiteurs benzoquinolone de vmat2
WO2012153341A1 (fr) 2011-05-12 2012-11-15 Arch Pharmalabs Limited Procédé pour la préparation d'iopéridone et sels pharmaceutiquement acceptables de celle-ci
WO2014047167A1 (fr) 2012-09-18 2014-03-27 Auspex Pharmaceuticals, Inc. Pharmacocinétiques de formulations d'inhibiteurs de benzoquinoline deutéré du transporteur 2 de monoamine vésiculaire
AU2013361459A1 (en) 2012-12-18 2015-07-02 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
EP3770159A1 (fr) 2013-01-31 2021-01-27 Auspex Pharmaceuticals, Inc. Inhibiteur benzoquinolone de vmat2
US9789072B2 (en) * 2013-06-19 2017-10-17 Som Innovation Biotech, S.L. Therapeutic agents for use in the propylaxis and/or treatment of hyperkinetic movement disorders
US20150133460A1 (en) 2013-11-11 2015-05-14 Millennium Phamaceuticals, Inc. Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
WO2015077521A1 (fr) 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Inhibiteurs benzoquinoline du transporteur de monoamine vésiculaire 2
EP3398602A1 (fr) 2014-01-27 2018-11-07 Auspex Pharmaceuticals, Inc. Inhibiteurs de benzoquinoline du transporteur de monoamine vésiculaire 2
NZ723107A (en) 2014-02-07 2022-11-25 Neurocrine Biosciences Inc Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
WO2015120110A2 (fr) 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Nouvelles formulations pharmaceutiques
RU2753740C2 (ru) 2014-05-06 2021-08-23 Ньюрокрайн Байосайенсиз, Инк. Лечение гиперкинетических двигательных расстройств
KR102586138B1 (ko) 2015-02-06 2023-10-05 뉴로크린 바이오사이언시즈 인코퍼레이티드 [9,10-디메톡시-3-(2-메틸프로필)-1H,2H,3H,4H,6H,7H,11bH-피리도-[2,1-a]이소퀴놀린-2-일]메탄올 및 그와 관련된 화합물, 조성물 및 방법
WO2016144901A1 (fr) 2015-03-06 2016-09-15 Auspex Pharmaceuticals, Inc. Méthodes de traitement de troubles des mouvements involontaires anormaux
AU2016282790B9 (en) 2015-06-23 2020-01-30 Neurocrine Biosciences, Inc. VMAT2 inhibitors for treating neurological diseases or disorders
CN115322188A (zh) 2015-10-30 2022-11-11 纽罗克里生物科学有限公司 Valbenazine盐及其多晶形物
WO2017084680A1 (fr) 2015-11-17 2017-05-26 Rontis Hellas S.A. Composition pharmaceutique contenant un médicament anti-inflammatoire non stéroïdien et un inhibiteur de pompe à protons
CN108925135A (zh) 2015-12-23 2018-11-30 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
JP2020500875A (ja) 2016-12-02 2020-01-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
JP7090151B2 (ja) 2017-01-27 2022-06-23 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
RU2771164C2 (ru) 2017-04-01 2022-04-27 Адептио Фармасьютикалз Лимитед (+)-альфа-дигидротетрабеназин для использования при лечении двигательного расстройства
CA3057548A1 (fr) 2017-04-01 2018-10-04 Adeptio Pharmaceuticals Limited Compositions pharmaceutiques
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
WO2018200605A1 (fr) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Utilisation de valbénazine pour le traitement de la dyskinésie induite par la lévodopa
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
JP2020520380A (ja) 2017-05-16 2020-07-09 ボウ リバー エルエルシー 処置法
MX2020002841A (es) 2017-09-21 2020-07-22 Neurocrine Biosciences Inc Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma.
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
AU2017435893B2 (en) 2017-10-10 2023-06-29 Neurocrine Biosciences, Inc Methods for the administration of certain VMAT2 inhibitors
WO2019104141A1 (fr) 2017-11-22 2019-05-31 Teva Pharmaceuticals Usa, Inc. Forme à l'état solide de valbénazine
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
WO2020037022A1 (fr) 2018-08-15 2020-02-20 Neurocrine Biosciences, Inc. Procédés d'administration de certains inhibiteurs de vmat2
SG11202111465RA (en) 2019-05-09 2021-11-29 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10689380B1 (en) 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Also Published As

Publication number Publication date
CA3076000A1 (fr) 2019-03-28
WO2019060322A3 (fr) 2019-05-02
MX2020002841A (es) 2020-07-22
US20210030744A1 (en) 2021-02-04
JP7250006B2 (ja) 2023-03-31
IL301770B1 (en) 2024-02-01
EP3684333A2 (fr) 2020-07-29
BR112020005373A2 (pt) 2020-09-24
CN111372567A (zh) 2020-07-03
JP2020534305A (ja) 2020-11-26
US11026939B2 (en) 2021-06-08
US11311532B2 (en) 2022-04-26
US20210030743A1 (en) 2021-02-04
WO2019060322A2 (fr) 2019-03-28
AU2018335259A1 (en) 2020-04-09
IL273300B1 (en) 2024-02-01
CN111372567B (zh) 2024-03-15
IL273300A (en) 2020-04-30
TW201919622A (zh) 2019-06-01
IL301770A (en) 2023-05-01
US20200276184A1 (en) 2020-09-03
IL309802A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
MA50175A (fr) Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés
MA52746A (fr) Molécules à utilité pesticide, compositions et procédés associés
MA49858A (fr) Composés, compositions et procédés
MA43380A (fr) Récepteurs chimériques modifiés et compositions et procédés associés
MA50063A (fr) Composés, compositions et procédés
DK3442973T3 (da) Hidtil ukendte forbindelser som autotaxinhæmmere og farmaceutiske sammensætninger omfattende samme
MA45779A (fr) Polypeptides immunomdulateurs et compositions et procédés associés
MA54875A (fr) Compositions oligonucléotidiques et procédés associés
MA46525A (fr) Anticorps anti-lag-3 et compositions
DK3368572T3 (da) Anti-pd-1-antistoffer og -sammensætninger
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA41558A (fr) Compositions d'allergènes mélangés et leurs procédés d'utilisation
BR112016020199A2 (pt) Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
MA45426A (fr) Procédés, kits, agents et appareils de transduction
ES2968227T3 (es) Compuestos, composiciones y procedimientos de uso
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
MA47613A (fr) Compositions et procédés de traitement du cancer
EP3310376A4 (fr) Agents thérapeutiques modifiés et compositions associées
CY1122287T1 (el) Ενωσεις χρησιμες για την αναστολη toy ror-γαμμα-τ
MA46865A (fr) Compositions de caryophyllène, appareils et procédés
DK3634377T3 (da) Farmaceutisk formulering
MA49837A (fr) Compositions pharmaceutiques
MA51162A (fr) Schémas posologiques et compositions et procédés associés
DK3265057T3 (da) Topisk formulering